Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer

Area of Science:

• Oncology
• Cancer Gene Therapy
• Stem Cell Therapy

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor prognosis.
• Effective therapies targeting PDAC's unique stromal microenvironment are needed.
• Current treatments have limited efficacy, necessitating novel therapeutic strategies.

Purpose of the Study:

• To develop and evaluate a novel cancer gene therapy for PDAC using adipose mesenchymal stromal/stem cells (AD-MSC).
• To assess the efficacy of AD-MSC engineered to release a soluble trimeric and multimeric variant of TNF-related apoptosis-inducing ligand (sTRAIL).
• To investigate the potential clinical translation of AD-MSC-mediated sTRAIL delivery for PDAC treatment.

Main Methods:

• AD-MSC were engineered to constitutively secrete sTRAIL.
• In vitro studies assessed sTRAIL stability and its ability to induce apoptosis in PDAC cell lines (BxPC-3, MIA PaCa-2) and primary cells.
• In vivo studies evaluated the anti-tumor efficacy of sTRAIL-releasing AD-MSC in a PDAC model, including tumor growth, cell markers, and angiogenesis.
• Histological analysis of patient PDAC specimens investigated TRAIL receptor expression (DR4, DR5, OPG).

Main Results:

• Engineered AD-MSC successfully released thermally stable sTRAIL.
• sTRAIL induced apoptosis in various PDAC cell lines and primary cells in vitro.
• In vivo, AD-MSC-delivered sTRAIL significantly inhibited tumor growth, reduced cytokeratin-7+ cells, and exhibited anti-angiogenic effects.
• Analysis of patient samples provided insights into TRAIL receptor expression relevant to treatment.

Conclusions:

• Adipose mesenchymal stem cells serve as efficient vehicles for delivering a novel sTRAIL variant.
• This gene therapy approach demonstrates significant preclinical efficacy against pancreatic ductal adenocarcinoma.
• The findings suggest promising opportunities for clinical translation in PDAC treatment.